Current, Former FDA Circ Panel Chairs Stress Need For Data On PFO Devices
This article was originally published in The Gray Sheet
Executive Summary
The medical community should curtail off-label use of patent foraman ovale closure devices and support ongoing randomized trials, according to a July 20 Journal of the American Medical Association column